JPRN-jRCT2011220013进行中（未招募）3 期
A Randomized, Open-Label, Multicenter Phase III Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin in Comparison With Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma
Shen Yin0 个研究点目标入组 222 人开始时间: 2022年8月4日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 222
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1, or 2
- •-CD20+ aggressive lymphoma as determined by the local hemopathology laboratory from the following diagnoses by 2016 World Health Organization classification of lymphoid neoplasms: DLBCL, not otherwise specified (NOS); high-grade B-cell lymphoma (NOS or double/triple hit); transformed follicular lymphoma; follicular lymphoma Grade 3b
- •-Have disease relapsed or refractory to at least one prior systemic therapy for aggressive non-Hodgkin's lymphoma (aNHL)
- •-Participants who have received only one prior line of therapy must be ineligible for autologous stem cell transplant (ASCT)
- •-Measurable disease
- •-Adequate hepatic, hematologic, and renal function
- •-Negative HIV test at screening. Participants with a positive HIV test at screening are eligible provided that, prior to enrollment, they are stable on anti-retroviral therapy for at least 4 weeks, have a CD4 count of at least 200 microliters, have an undetectable viral load, and have not had a history of opportunistic infection attributable to AIDS within the last 12 months
排除标准
- •-Pregnant or breast feeding, or intending to become pregnant during the study or within 3 months after the final dose of mosunetuzumab, 9 months after the final dose of polatuzumab vedotin, 12 months after the final dose of rituximab, 6 months after the final dose of gemcitabine, 9 months after the final dose of oxaliplatin, and 3 months after the final dose of tocilizumab, as applicable
- •-Inability to comply with protocol-mandated activity restrictions
- •-Prior treatment with mosunetuzumab or other CD-20-directed bispecific antibodies or R-GemOx or Gem-Ox
- •-Prior treatment with polatuzumab vedotin, with the following exceptions: participants who have a documented response (partial response or complete response) to polatuzumab vedotin and an absence of PD within 12 months from the last dose of polatuzumab vedotin; participants who received up to 2 doses of a polatuzumab vedotin-containing regimen as bridging to CAR-T therapy, and either has a documented disease control (stable disease, partial response, or complete response), or were not assessed for response following treatment with polatuzumab vedotin
- •-Contraindication to any component of the study treatment
- •-Grade > 1 peripheral neuropathy
- •-Received anti-lymphoma treatments with monoclonal antibodies, radio-immunoconjugates or antibody-drug conjugates (ADCs) within 4 weeks before the first dose of study treatment
- •-Treatment with any chemotherapeutic agent, or treatment with any other anti-cancer agent (investigational or otherwise) within 4 weeks or 5 half-lives of the drug, whichever is shorter, prior to the first dose of study treatment
- •-Treatment with radiotherapy within 2 weeks prior to the first dose of study treatment
- •-ASCT within 100 days prior to the first study treatment administration
- •-Prior treatment with chimeric antigen receptor (CAR) T cell therapy within 30 days before the first study treatment administration
- •-Prior allogenic stem cell transplant (SCT)
- •-Known or suspected history of hemophagocytic lymphohistiocytosis (HLH)
- •-History of confirmed progressive multifocal leukoencephalopathy
- •-History of severe allergic or anaphylactic reactions to monoclonal antibody therapy
- •-History of other malignancy that could affect compliance has been treated with the protocol or interpretation of results, with the exception of malignancies with a negligible risk of metastasis or death.
- •-Currently have or have had a past history of central nervous system (CNS) involvement of lymphoma
- •-Current or past history of CNS disease, such as stroke, epilepsy, CNS vasculitis, or neurodegenerative disease.
- •-Significant cardiovascular disease such as New York Heart Association Class III or IV cardiac disease, myocardial infarction within the last 6 months, unstable arrhythmias, or unstable angina
- •-Significant active pulmonary disease
- •-Known or suspected chronic active Epstein-Barr virus (EBV) infection
- •-Recent major surgery within 4 weeks prior to the first study treatment administration
- •-Have been administered a live, attenuated vaccine within 4 weeks before the first dose of study treatment administration or anticipation that such a live, attenuated vaccine will be required during the study
- •-Participants who have positive SARS-CoV-2 test within 7 days prior to enrollment (rapid antigen test result is acceptable)
- •-History of autoimmune disease
- •-Received investigational therapy, whether or not intended for lymphoma treatment, within 7 days prior to initiation of study treatment
- •-Clinically significa
研究者
相似试验
进行中（未招募）
3 期
Phase III study of belantamab mafodotin, bortezomib, and dexamethasone (B-Vd) versus daratumumab, bortezomib, and dexamethasone (D-Vd) in participants with relapsed/refractory multiple myelomaMultiple MyelomaJPRN-jRCT2011210001Ishibashi Hideyasu478
进行中（未招募）
1 期
Treatment combination of Durvalumab, Tremelimumab, Enfortumab Vedotin in patients with muscle invasive bladder cancer ineligible to cisplatiEUCTR2020-005452-38-GRAstraZeneca AB830
进行中（未招募）
1 期
Treatment combination of Durvalumab, Tremelimumab, Enfortumab Vedotin in patients with muscle invasive bladder cancer ineligible to cisplatiCisplatin ineligible patients with histologically or cytologically documented muscle-invasive transitional cell carcinoma (TCC) of the bladder.MedDRA version: 20.0Level: LLTClassification code 10005004Term: Bladder cancer NOSSystem Organ Class: 100000004864EUCTR2020-005452-38-ESAstraZeneca AB830
进行中（未招募）
1 期
Treatment combination of Durvalumab, Tremelimumab, Enfortumab Vedotin in patients with muscle invasive bladder cancer ineligible to cisplatin or Who Refuse CisplatiEUCTR2020-005452-38-NLAstraZeneca AB830
进行中（未招募）
1 期
Treatment combination of Durvalumab, Tremelimumab, Enfortumab Vedotin in patients with muscle invasive bladder cancer ineligible to cisplatin or Who Refuse CisplatiEUCTR2020-005452-38-ATAstraZeneca AB830